Thermal ablation and cryotherapy for cervical precancer
Destroying precancerous cervical cells with a heated or frozen probe in under a minute, the tool that makes screen-and-treat possible where there are no surgeons.
WHO (2019) recommends thermal ablation (100°C probe, 20-40 seconds) or cryotherapy for eligible CIN2+ lesions in screen-and-treat programmes, often after visual inspection with acetic acid (VIA) or HPV testing. Portable battery-powered devices cost a few hundred dollars; cure rates ~85-95% for eligible lesions. Central to the WHO cervical cancer elimination strategy's 90% treatment target.
How it works
Coagulative necrosis (thermal) or freeze-thaw injury (cryo) of the cervical transformation zone.
- Cheap, fast, no anaesthesia or electricity mains
- Enables single-visit screen-and-treat
- No histology
- Not suitable for large or endocervical lesions
Latest papers
topQuery for this technology: (TITLE:"Thermal ablation and cryotherapy for cervical precancer" OR ABSTRACT:"Thermal ablation and cryotherapy for cervical precancer") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Thermal ablation and cryotherapy for cervical precancer, not a curated reading list.